The U.S. FDA launched a pilot program pairing sponsors with prequalified research institutions to speed investigational new drug (IND) application preparation and reduce delays between pre-IND planning and first-in-human trial initiation. The agency said it will enable rolling reviews of components during the pre-IND phase rather than waiting for all materials at once. The initiative aims to streamline parallel workstreams—such as IRB assessment and site activation—while generating evidence on modernizing early-stage support processes. For sponsors, it signals a more structured approach to accelerating clinical timelines without changing core scientific and ethical obligations.